STOCK TITAN
  1. Home
  2. News
  3. ABVC

ABVC BioPharma Inc - ABVC STOCK NEWS

Welcome to our dedicated news page for ABVC BioPharma (Ticker: ABVC), a resource for investors and traders seeking the latest updates and insights on ABVC BioPharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ABVC BioPharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ABVC BioPharma's position in the market.

News
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share
Rhea-AI Summary
ABVC BioPharma, Inc. has signed a definitive agreement to acquire real estate in Taoyuan City, Taiwan, estimated at approximately $2.96 million. The acquisition aims to develop plant factories for ABVC’s botanical pipeline and establish a base for Good Agricultural Practices fields. The company will issue shares of common stock and a warrant to purchase up to 1,000,000 shares of common stock in consideration for ownership of the property. The acquisition is expected to raise shareholders' equity and facilitate ABVC’s drug development plan, generating future revenue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
acquisition
-
News
ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees
Rhea-AI Summary
ABVC BioPharma, Inc. (NASDAQ: ABVC) and its subsidiary BioLite, Inc. announced that they received 46 million shares from AiBtl BioPharma Inc. as the first milestone payment under a global licensing agreement. The agreement values the payment at $460. The Company's pipeline of products has excellent market potential, with the MDD market expected to reach $14.96 billion by 2032 and the global ADHD treatment market expected to grow at a CAGR of 7.3% between 2023-2032.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
60.83%
Tags
none
-
News
ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study
Rhea-AI Summary
ABVC BioPharma, Inc. (NASDAQ: ABVC) provided an update on the eight-week long ADHD Phase II part II clinical study at the University of California San Francisco Medical Center and five Taiwanese medical centers. Out of 94 screened subjects, 69 enrolled, and 60 completed the study. The Phase II part I clinical study successfully achieved primary endpoints and was accepted by the FDA. The CEO expects positive results in the interim analysis report and plans to continue the study by enrolling another thirty patients. The global ADHD treatment market is projected to reach $32.14 billion by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.41%
Tags
clinical trial
News
ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials
Rhea-AI Summary
ABVC BioPharma, Inc. (ABVC) shared an interview with Dr. Scott Irwin, MD, Ph.D., the Principal Investigator for the clinical trials of ABV-1601, the Company’s drug under development to treat depression in cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
clinical trial
-
News
ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market
Rhea-AI Summary
ABVC BioPharma, Inc. (ABVC) announced the receipt of a U.S. patent for PDC-1421, a Radix Polygala extract used in their asset ABV-1505 targeting ADHD. The patent grants exclusivity until 2040. ABVC is awaiting patent applications in the EU, China, and Japan. ABV-1505, a botanical-based NET inhibitor, is in Phase IIb clinical studies for ADHD treatment. The global ADHD treatment market is projected to reach $32.14 billion by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.33%
Tags
none
-
News
ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M
Rhea-AI Summary
ABVC BioPharma, Inc. (NASDAQ: ABVC) announced a global licensing definitive agreement with AiBtl BioPharma Inc. for its CNS drugs targeting Major Depressive Disorder and Attention Deficit Hyperactivity Disorder. The agreement has the potential of licensing income worth $467M and royalties up to $200M. The Licensed Products were valued at $667M by a third-party evaluation. ABVC and AiBtl are determined to work together to strengthen their new drug development and business collaboration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.2%
Tags
none
News
ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results
Rhea-AI Summary
ABVC BioPharma, Inc. (NASDAQ: ABVC): ABVC BioPharma, a biotechnology company, announced its financial and operating results for the third quarter of 2023, including a securities purchase agreement with Lind Global Fund II, LP. The company's quarterly report on Form 10-Q provides detailed financial statements and comparisons on a year-over-year basis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.61%
Tags
earnings
-
News
ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million
Rhea-AI Summary
ABVC BioPharma enters into a multi-year licensing agreement with AiBtl BioPharma for CNS drugs in MDD and ADHD. The licensed products were valued at $667M. ABVC will receive 46 million shares of AiBtl stock and milestone cash payments of $7M with royalties of 5% of net sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
50.59%
Tags
none
-
News
ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study
Rhea-AI Summary
ABVC BioPharma provides an update on its ADHD Phase IIb clinical study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.02%
Tags
clinical trial
News
ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)
Rhea-AI Summary
ABVC BioPharma receives Taiwanese patent for treatment of Major Depressive Disorder
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.94%
Tags
none
Stock ABVC logo
ABVC BioPharma Inc

Nasdaq:ABVC

ABVC Rankings

#5270 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ABVC Stock Data

11.83M
6.80M
26.97%
2.43%
12.47%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Fremont

About ABVC

american brivision (holding) corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the united states. the company is developing abv-1501, a combination therapy for triple negative breast cancer; abv-1504 for major depressive disorders; abv-1505 for attention deficit hyperactivity disorder; abv-1703 for the treatment of pancreatic cancer; abv-1702 to treat myelodysplastic syndromes; and abv-1601 for treating depression in cancer patients. it has a co-development agreement with rgene corporation; collaboration agreement with biohopeking corporation to develop abv-1501; and collaborative agreement with biofirst corporation to co-develop bfc-1401 vitreous substitute for vitrectom; and license with biofirst corporation to research and develop a medical device, abv-1701 vitargus for the treatment of retinal detachment or vitreous hemorrhage. the company was founded in 2015 and is based in fremont, california. american br